Victor J Marder Selected Research

Fibrinolysin

10/2013	Comparison of local thrombolytic efficacy of plasmin and rt-PA in an in-vitro flow system; a pilot study.
5/2012	Safety evaluation of a recombinant plasmin derivative lacking kringles 2-5 and rt-PA in a rat model of transient ischemic stroke.
8/2011	Comparison of plasmin with recombinant tissue-type plasminogen activator in lysis of cerebral thromboemboli retrieved from patients with acute ischemic stroke.
10/2010	Haemostatic safety of a unique recombinant plasmin molecule lacking kringles 2-5.
10/2010	Thrombolysis with plasmin: implications for stroke treatment.
1/2009	Thrombolytic therapy for deep vein thrombosis: potential application of plasmin.
1/2008	Pre-clinical studies of plasmin: superior benefit-to-risk ratio of plasmin compared to tissue plasminogen activator.
2/2004	Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?
4/2003	Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage.
7/2002	Towards safer thrombolytic therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Victor J Marder Research Topics

Disease

8	Hemorrhage 09/2011 - 07/2002
6	Ischemic Stroke 05/2012 - 07/2002
5	Myocardial Infarction 02/2004 - 01/2002
4	Stroke (Strokes) 05/2012 - 08/2006
3	Venous Thromboembolism 11/2012 - 05/2005
3	Thrombosis (Thrombus) 08/2011 - 07/2002
2	Thrombocytopenia (Thrombopenia) 07/2012 - 12/2005
2	Intracranial Hemorrhages (Intracranial Hemorrhage) 05/2012 - 04/2003
2	Infarction (Infarctions) 05/2012 - 02/2004
2	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 09/2011 - 10/2010
2	Arterial Occlusive Diseases (Arterial Occlusive Disease) 10/2010 - 01/2008
2	Venous Thrombosis (Deep-Vein Thrombosis) 01/2009 - 07/2002
2	Wounds and Injuries (Trauma) 01/2008 - 07/2002
1	Hereditary Hemorrhagic Telangiectasia 06/2015
1	Gastrointestinal Hemorrhage (Hematochezia) 06/2015
1	Thrombotic Thrombocytopenic Purpura 04/2014
1	Flushing 10/2013
1	Body Weight (Weight, Body) 10/2010
1	Intermittent Claudication 02/2004
1	Peripheral Arterial Disease 02/2004
1	Dyslipidemias (Dyslipidemia) 12/2003
1	Hypertension (High Blood Pressure) 04/2003
1	Cardiovascular Diseases (Cardiovascular Disease) 04/2003
1	Pulmonary Embolism 07/2002

Drug/Important Bio-Agent (IBA)

10	Fibrinolysin FDA Link 10/2013 - 07/2002
6	Hemostatics (Antihemorrhagics)IBA 10/2010 - 04/2003
5	Fibrinolytic Agents (Antithrombotic Agents)IBA 10/2013 - 04/2003
5	AnticoagulantsIBA 11/2012 - 07/2002
5	Tissue Plasminogen Activator (Alteplase)FDA Link 05/2012 - 04/2003
5	Plasminogen Activators (Plasminogen Activator)IBA 10/2010 - 04/2003
3	Fibrinogen (Factor I)FDA Link 11/2011 - 04/2003
2	Heparin (Liquaemin)FDA LinkGeneric 07/2012 - 12/2005
2	FibrinIBA 11/2011 - 08/2006
2	fibrin fragment D (D-dimer)IBA 08/2011 - 04/2003
2	Biomarkers (Surrogate Marker)IBA 05/2005 - 02/2004
2	LipidsIBA 02/2004 - 04/2003
2	Antifibrinolytic Agents (Antifibrinolytics)IBA 04/2003 - 07/2002
2	C-Reactive ProteinIBA 04/2003 - 01/2002
1	Bevacizumab (Avastin)FDA Link 06/2015
1	ADAMTS13 ProteinIBA 04/2014
1	NucleotidesIBA 04/2014
1	Enoxaparin (Lovenox)FDA LinkGeneric 11/2012
1	N(4)-oleylcytosine arabinosideIBA 11/2012
1	apixabanIBA 11/2012
1	RivaroxabanIBA 11/2012
1	Dabigatran FDA Link 11/2012
1	lepirudin (Refludan)FDA Link 07/2012
1	HirudinsIBA 07/2012
1	AntithrombinsIBA 07/2012
1	desirudin (Iprivask)FDA Link 07/2012
1	Ancrod (Arvin)IBA 11/2011
1	VenomsIBA 11/2011
1	Thrombin FDA Link 10/2010
1	Immunoglobulin G (IgG)IBA 12/2005
1	AntibodiesIBA 12/2005
1	Platelet Factor 4IBA 12/2005
1	PlasminogenIBA 02/2004
1	lipoprotein cholesterolIBA 12/2003
1	Factor VIII (Coagulation Factor VIII)IBA 04/2003
1	von Willebrand FactorIBA 04/2003
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 07/2002
1	Serum Amyloid A Protein (Serum Amyloid A)IBA 01/2002

Therapy/Procedure

5	Therapeutics 10/2010 - 02/2004
3	Catheters 10/2010 - 07/2002
2	Thrombolytic Therapy 01/2009 - 02/2002
1	Ligation 05/2012
1	Thrombectomy 05/2011
1	Renal Dialysis (Hemodialysis) 01/2008